PIH48 RELATIONSHIP BETWEEN DRUG COST COVERAGE AND PRESCRIPTION DECISION MAKING IN MEDICARE PART D ENROLLEES  by Hales, JW et al.
A170 Abstracts
date of the subjects with the disease. Hourly productivity was units produced per hour
worked during the year. Annual productivity was total units produced during the year.
Incremental productivity  adjusted differences between the disease cohort and the 
controls and considered signiﬁ cant at P a 0.05. RESULTS: Employees with productiv-
ity eligibility for the disease/controls were: BPD 59/27,574; OMD 1,382/25,268; CC 
82/27,276; FD 73/27,513; GERD 541/26,775; gout 86/27,472; and insomnia
415/26,240. Hourly productivity results (incremental units per hour worked; percent
disease/control; signiﬁ cance) were: CC (1.26; 106.6%; P  0.05); insomnia (0.46;
102.5%; P  0.05), OMD (0.41; 102.0% P  0.05), GERD (0.849; 95.6%; P 
0.0481), gout (0.65; 96.5%; P  0.05), BPD (1.35; 93.5%; P  0.05); and FD (1.73;
90.8%; P  0.05). Annual productivity results (incremental units per year; percent 
disease/control; signiﬁ cance) were: GERD (1754; 94%; P  0.0391), OMD (414; 
101.2%; P  0.05); CC (194; 100.7%; P  0.05); gout (566; 98.0%; P  0.05), 
insomnia (925; 96.8%; P  0.05), FD (3,022; 89.1%; P  0.05); and BPD (7,103; 
79.9%; P  0.0001). CONCLUSIONS: Employees with GERD have signiﬁ cant
decreases in both annual and hourly productivity. Employees with BPD experienced
a signiﬁ cant decrease in annual productivity but not in hourly productivity. Many
comparisons were not signiﬁ cant, which contradicts some self reported data indicating
impairment due to the conditions.
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OBJECTIVES: The productivity costs of intimate partner violence (IPV) have received
considerable attention by human resource experts, employers and news outlets, includ-
ing the BBC and Washington Post. Absences, tardiness and turnover have been esti-
mated. Yet, validated estimates of “presenteeism” (functioning at work) are unknown. 
METHODS: In 2007, 190 female IPV victims petitioning a US court for orders for 
protection (OP) consented to participate in a randomized control trial which included 
the validated Work Limitations Questionnaire, the SF-12v2, the CES-D (for depression
and anxiety), the CTS2S and the Danger Assessment. The WLQ is sensitive to changes
in depression and anxiety over time and to a variety of medical and behavioral health 
conditions. We report descriptive statistics and univariate comparisons of working and 
non-working subjects using the WLQ. The paper will include multivariate analyses 
controlling for mental health and overall health status, neighborhood poverty rates 
and household characteristics, and comparisons among scales of speciﬁ c domains 
(time management, mental/social performance, physical, output). The sample is com-
prised of 122 subjects who completed time two assessments. RESULTS: Employed 
subjects report a mean WLQ Productivity Loss Score of 94.3 (range 75.13–100; s.d. 
6.28), representing a performance loss while working, of 5.7% (or 4.6 hours over 2
weeks of full-time employment) compared to the healthy worker norm. Employed
women (n  75) reported better health, less danger, and less severe mental health 
symptoms than those outside of the workforce (n  47) at the time of their OP Peti-
tions. CONCLUSIONS: To our knowledge, these are the ﬁ rst estimates of work loss
reported by IPV victims. When considered on a continuum of burden of illness due
to work productivity loss, preliminary data suggest this population has a greater 
burden of illness than breast cancer survivors, but a lower burden than employees
with active major clinical depression.
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THE IMPACT OF MEDICARE PART D ON HEALTH CARE UTILIZATION
AND HEALTH OUTCOMES FOR MEDICARE BENEFICIARIES WITHOUT 
PREVIOUS DRUG COVERAGE
LIU/Mr XQ, Walton SM, Crawford SY, Pickard AS
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OBJECTIVES: To examine, using nationally representative data, the impact of Medi-
care Part D on medication utilization, out-of-pocket-costs, non-drug medical service 
utilization, and health outcomes among civilian non-institutionalized Medicare beneﬁ -
ciaries without prescription drug coverage prior to the implementation of Medicare 
Part D. METHODS: The primary data were from the Medical Expenditure Panel 
Survey (MEPS) panel 10 data and the corresponding 2005 and 2006 pharmacy com-
ponent data. This study included Medicare beneﬁ ciaries between 65 and 79 years old 
that had only Medicare Fee for Service (FFS) in 2005. Patients between 55 and 63 
years old with no drug coverage in 2005 served as control subjects. Difference-in-dif-
ferences was used to identify the effects of Medicare Part D on health care utilization,
expenditures, non-drug medical service utilization, and health outcomes among Medi-
care beneﬁ ciaries. RESULTS: The mean amount paid by the near elderly without 
insurance in 2005 declined 7.8%, while the mean amount paid by Medicare beneﬁ -
ciaries with Medicare FFS only in 2005 decreased 40.6%. The number of prescription 
reﬁ lls of the near elderly increased 10.35%, while there was only 4.3% increase among
the Medicare beneﬁ ciaries. ER visits among the Medicare FFS group declined 2.6%, 
while the number of ER visits among the near elderly increased 0.94%. There was 
only small growth rate difference in other outcomes variable. CONCLUSIONS: Evi-
dence from the MEPS data set suggests that Medicare Part D reduced out of pocket 
costs, drug utilization, and ER visits among patients without prior coverage. While 
cost reduction was expected, the reduction in utilization of drugs was not. Future 
research should further examine these trends.
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MANDATE
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OBJECTIVES: To estimate the proportion of all very-low and moderately-low-birth-
weight (VLBW, MLBW) infants and the short-term costs associated with fertility 
therapy in an insured population with a state mandate that requires coverage for fertil-
ity drugs but not in vitro fertilization (IVF) or drugs used with IVF. METHODS: The 
study sample consists of all live births, 2003–2007, that could be linked to mothers
with continuous pharmacy and medical beneﬁ ts eligibility during the 11 months before
delivery, within a geographically deﬁ ned subset of a commercially insured population. 
Likely causal relationships with fertility therapy are deduced and categorized as clo-
miphene or follicle-stimulating hormone (FSH) / intrauterine insemination (IUI) or 
IVF, based on the intervals between the dates of delivery and claims for IUI, clomi-
phene, FSH, or embryo transfer. Birthweight is categorized from claims coding. Mater-
nal and infant claims charge distributions are characterized. RESULTS: Of 31,708 live 
births from 30,905 deliveries by 27,195 distinct women, clomiphene, FSH, and FSH 
 IVF categories respectively account for 4.2%, 2.8%, 0.7% of the total number;
8.9%, 16.4%, 3.9% of all VLBW; 8.7%, 12.1%, 3.5% of all MLBW. Mean infant
charges during the 12 months after birth were not signiﬁ cantly different from other 
infants in the same birthweight categories. Mean charges during ﬁ rst 12 months for
all VLBW, MLBW, and other infants were, respectively, $248,600, $33,560, $6,990, 
and low-birthweight infants collectively accounted for 41.6% of all claims charges
for infants. Differences in mean maternal charges are explained by fertility therapy, 
Caesarian section, and multiple gestation. CONCLUSIONS: Analysis of administra-
tive claims data can supplement IVF registry data and published single or multicenter
studies to inform models that predict outcomes and costs associated with different 
policy choices.
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OBJECTIVES: Japanese version of Beers criteria (JP-BC) for potentially inappropriate 
medications in elderly patients was developed by consensus among nine specialists in
order to reﬂ ect regional medical practice and available medications. The prevalence of, 
and risk factors and medical costs associated with JP-BC were examined. METHODS:
A cross-sectional study was conducted using health insurance claims data in Japan. 
Patients aged 65 years or older and had a pharmacy claim between October 2006 and
September 2007 were selected and the use of JP-BC was identiﬁ ed. Associations with
patient demographics, health care utilization patterns and co-morbidities were assessed 
using logistic regression models. Medical costs associated with the JP-BC were also
examined using generalized linear models. RESULTS: Among 6991 old patients, 
41.2% were used one of the JP-BC. Commonly used medications were H2 blockers
(19.5%), benzodiazepines (10.9%) and anticholinergics and antihistamines (7.8%).
Patients with multiple medications, long-term inpatient care and multiple chronic
conditions including gastrointestinal and cardiovascular diseases were more likely to 
use JP-BC. Mean annual cost for JP-BC users was 517,516 yen (5,625 US$), which 
was 2.4 times higher than that in non JP-BC users. Cost differences were still observed
after risk adjustment using Charlson or Elixhauser co-morbidities. High medical costs 
among JP-BC users were partly explained by their high likelihood of multiple medica-
tions and long-term inpatient care. CONCLUSIONS: The prevalence of potentially 
inappropriate medication use in Japan was relatively higher than those previously 
reported in other countries even though regional speciﬁ c medications were considered. 
Drug utilization reviews using the criteria must be promoted to increase awareness of 
inappropriate pharmaceutical cares among elderly and control medical costs.
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OBJECTIVES: The Medicare Part D prescription drug beneﬁ t was introduced for 
Medicare enrollees to obtain prescription drug coverage. The 2006 beneﬁ t did not
provide insurance coverage for standard prescription drug plan (PDP) members who 
incurred prescription costs between $2250 and $3600 dollars (referred to as the 
“doughnut hole”). We evaluated whether the “doughnut hole” was a factor in altering
the prescription fulﬁ llment decisions of Part D members. METHODS: In the current 
retrospective cohort study, 750 pharmacy adjudication records from a national Part
D HMO pharmacy database were investigated for the year 2006. Five hundred par-
ticipants (standard PDP members) without coverage in the doughnut hole were com-
pared to a group of 250 participants (enhanced PDP members) whose prescription
coverage did not lapse in the doughnut hole. All participants were analyzed via a 
multivariate strategy for their prescription fulﬁ llment decisions which were recorded
as an endpoint of ﬁ lling, delaying, switching, or stopping their respective medication. 
RESULTS: From 72% of the standard PDP members who experienced the doughnut 
hole and altered their prescription decision, it was determined that 22% delayed
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medication, 13% switched medication, 10% both delayed and stopped medication
while 9% of members both switched and delayed medication. The data show people
who experienced the doughnut hole are 1.3 times more likely to switch, 2 times more
likely to delay, 3 times more likely to switch and delay, and 4.7 times more likely to 
switch, stop, and delay their prescription medications. CONCLUSIONS: The results 
of the study suggest that the doughnut hole is a factor in alteration of prescription 
fulﬁ llment decisions by Part D members. Because patient non-compliance of medica-
tions may result in mortality it is important that the Medicare Part D standard pre-
scription drug plan be designed to limit excessive ﬁ nancial burden to members based
on spending levels.
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OBJECTIVES: This analysis was intended to identify trends in Hormone Replacement 
Therapy (HRT) use in female seniors on public drug programs in 5 Canadian provinces 
between 2001–2002 and 2006–2007. METHODS: Claims level data were analyzed
for female seniors on public drug programs in Alberta, Saskatchewan, Manitoba, New 
Brunswick and Nova Scotia. The analysis included calculation of the proportion of 
female seniors on these programs using HRT, and also examined trends in the dosage
and type of therapy used. RESULTS: The rate of HRT use among female seniors in
the 5 provinces dropped from 13.9% in 2001–2002 to 5.2% in 2006–2007. The
decrease in combination HRT use (24.9% per year) was greater than the decrease in 
estrogen only HRT use (14.7% per year). The vast majority of female seniors still 
using HRT in 2006–2007 were on estrogen-only regimens (84%). Of women using 
the higher (0.625 mg) dose in 2001–2002 and still using HRT in 2006–2007, 37%
had switched to the lower (0.3 mg) dose. CONCLUSIONS: This analysis provides
insight into how new evidence affected HRT use in Canadian female seniors. The 
decline in HRT use observed was consistent with the results of other studies examining 
use during this time period. The majority of women still using HRT at the end of the 
study period were on estrogen-only regimens, with over a third of these women using
a lower dose.
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OBJECTIVES: The purpose of this study was to determine the extent of use, during
pregnancy, of medication(s) containing the active pharmaceutical ingredient(s) (API) 
classiﬁ ed to be teratogenic by the FDA. METHODS: This retrospective study analyzed 
the two 2005 cross-sectional databases of the National Ambulatory Medical Care
Survey (NAMCS) and the outpatient (OPD) section of the National Hospital Ambula-
tory Medical Care Survey (NHAMCS). Pregnant women who were prescribed terato-
genic APIs categorized by FDA as X or D were included in the study. The un-weighted 
data from NAMCS and NHAMCS were used to compute the Chi-square test statistics. 
RESULTS: Of 2,228 pregnancy related ambulatory visits, 22.94% were physician-
ofﬁ ce (PO) visits, and 77.06% were OPD visits. Medications were prescribed during
63.5% of the ambulatory visits. Category-X and/or D APIs were prescribed during
131 of these visits, comprising of 74.81% PO-visits and 25.19% OPD-visits. Chi-
square analysis between the number of visits [when APIs with Risk Categories (X, D, 
and X-and-D) were prescribed] and the trimester was signiﬁ cant (p  0.021) among 
PO-visits, but not signiﬁ cant among OPD-visits. During the PO-visits, Category-D 
APIs were most frequently prescribed in the 3rd trimester, while Category-X APIs were 
only prescribed in the 1st trimester. During the 131 visits, 158 Category-X and/or D 
APIs were prescribed, with 70.9% prescribed during PO-visits, and 29.1% during 
OPD-visits. Chi-square analysis between the number of APIs [with Risk Categories] 
and the trimester, was signiﬁ cant (p  0.025) among OPD-visits but not signiﬁ cant 
among PO-visits. During OPD-visits, the numbers of Category-X and Category-D 
APIs prescribed increased with the progression of the pregnancy. CONCLUSIONS:
This study showed that APIs with teratogenic effect were prescribed to pregnant 
women, particularly during 3rd trimester, with Category-D prescriptions being more 
than that of Category-X. A greater number of Category-D and X prescriptions was 
written during hospital-visits than physician-ofﬁ ce visits.
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OBJECTIVES: We sought to examine racial and ethnic disparities in prescription drug
use among the U.S. older adult population. METHODS: The National, Social life,
Health and Aging Project (NSHAP) was used for this analysis. NSHAP is a nationally 
representative probability sample of 3,005 community-dwelling persons 57 to 85 years
of age from households across the United States. Household interviews were con-
ducted between July 2005 and March 2006. Multivariate logistic regression was used 
to examine the factors associated with differences in prescription medication use 
among non-Hispanic whites (Whites), non-Hispanic blacks (Blacks), and Hispanics
(any race). RESULTS: In unadjusted analyses, in comparison to Whites, the use of at
least one prescription medication was similar in Blacks (odds ratio [OR] 1.15, 95%
conﬁ dence intervals [CI] 0.80, 1.57), but signiﬁ cantly less among Hispanics (OR 0.49, 
CI 0.38, 0.73). After adjusting for demographic and health-related characteristics
including diagnosed medical conditions, Whites were signiﬁ cantly more likely to be 
using a prescription medication than either Blacks (OR 0.68, CI 0.49, 0.94) or Hispan-
ics (OR 0.52, CI 0.37, 0.73). Racial/ethnic disparities for Hispanics were signiﬁ cantly 
reduced (OR 0.73, CI 0.47, 1.14) after accounting for insurance status and usual 
source of care, and racial/ethnic disparities varied by therapeutic drug class. CON-
CLUSIONS: These data provide updated, nationally representative estimates of racial 
and ethnic differences in prescription medication use among community dwelling 
elders. hile differences in demographic and health characteristics did not explain the 
observed disparities in prescription drug use for blacks, socio-economic and access to 
care disparities may. However, differences in access to care were more important for 
Hispanics. In addition, differences in the use of over-the-counter drugs and dietary
supplements is also evident.
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OBJECTIVES: Given the complexity of the Medicare Part D prescription drug beneﬁ t
and annual plan changes, many Medicare beneﬁ ciaries often lack knowledge and skills
needed to select an optimal Part D plan. Through community outreach events targeted
toward underserved populations, we sought to minimize beneﬁ ciaries’ out-of-pocket
(OOP) prescription drug costs. We also examined the relationship between additional 
governmental assistance and potential OOP cost savings. METHODS: Students from 
seven California Schools of Pharmacy were trained to provide one-on-one Part D 
counseling, under faculty supervision. Students obtained the 2009 annual estimated 
costs for each participant’s current stand-alone prescription drug plan (PDP), and 
compared these costs to the lowest-cost plan (if different), using the online Medicare
Prescription Drug Plan Finder tool. Additionally, each participant’s current plan cost
ranking was compared to the 51 PDPs offered in California (2009) and recorded along 
with subsidy status. RESULTS: During 43 statewide outreach events, pharmacy stu-
dents counseled 661 beneﬁ ciaries enrolled in a PDP, of whom 519 (79%) were receiv-
ing governmental assistance with their prescription medication costs (i.e., Medicaid 
or the low-income subsidy). Beneﬁ ciaries were, on average, enrolled in the 12th-
lowest-cost plan (out of 51) in terms of OOP plan costs, and 496 (75%) beneﬁ ciaries 
had potential OOP savings by switching to a lower-cost plan. Those receiving a
subsidy had a lower annual mean OOP potential cost savings than non-subsidized 
beneﬁ ciaries ($399 vs. $587, p  0.0001). However, they had a higher mean percentage
of potential cost-savings relative to the annual cost of their current plan (51% vs. 
32%, p  0.0001). CONCLUSIONS: More than three-fourths of the beneﬁ ciaries in 
this study were not in the PDP with the lowest OOP medications costs. Our data 
suggest that Medicare beneﬁ ciaries, regardless of income, can optimize their prescrip-
tion drug plan choices through outreach interventions conducted by pharmacy stu-
dents with Part D expertise.
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COST-RELATED NONADHERENCE TO PRESCRIPTION DRUGS? AN
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OBJECTIVES: Cost-related nonadherence to prescription drugs (CRN) can result in
unfavorable health conditions. The objective of this study was to examine the relation-
ship between CRN and elements in Part D plan beneﬁ t design. METHODS: This 
was a cross-sectional study using the 2006 Medicare Consumer Assessment of 
Healthcare Providers and Systems (CAHPS) data. We augmented the CAHPS data 
with the Centers for Medicare & Medicaid Services (CMS) plan beneﬁ t design infor-
mation, CMS Hierarchical Condition Category scores and a composite socioeconomic 
indicator derived from U.S. Census data. We examined the relationship using survey
logistic modeling. Our analytic data included survey respondents enrolled in a stand-
alone prescription drug plan (PDP) or Medicare Advantage drug plan (MA-PD) in
2006. Individuals who were identiﬁ ed by CMS as having other creditable drug cover-
age, deemed low-income subsidy, or enrolling in MA cost plans were excluded. 
RESULTS: About one-quarter (weighted percentage) of the study sample (unweighted 
N  133,616; weighted N  11,008,931) was enrolled in an MA-PD. Overall, 24 %
of the sample enrolled in a plan with drug deductibles, 87% had tiered copayments, 
59% were in plans requiring prior authorization or step therapy for eight or more 
of the top 100 drugs, and 94% offered mailorder services. After adjusting for 
other variables, we found MA-PD enrollment was associated with higher reported
CRN compared with PDP enrollment. Additionally, plans with drug deductibles, 
tiered copayments, or mailorder services, were also associated with higher reported 
CRN (OR [95% CI]  1.12 [1.03–1.21], 1.21 [1.04–1.39], 1.24 [1.06–1.46], respec-
tively). Plans requiring prior authorization or step therapy for eight or more of the
top 100 drugs did not present increased risk for CRN. CONCLUSIONS: Medicare 
